Neurology Insights: J&J Drops Seltorexant from Alzheimer's Pipeline
Understanding J&J's Decision on Seltorexant
J&J's recent move to drop seltorexant, a key player in their neurology pipeline, has sent ripples through the Alzheimer’s research community. Initially heralded as a promising candidate, this human orexin-2 receptor selective agonist showed positive results in a Phase III trial earlier this year as an adjuvant therapy.
The Impact on Alzheimer's Research
Despite the potential benefits of seltorexant, its removal signifies a setback in the quest for effective Alzheimer’s treatments. Neurology experts are now left to reassess strategies and focus on the next generation of therapeutic candidates.
- Seltorexant was a promising candidate.
- Positive Phase III trial results.
- Challenges remain in Alzheimer's treatment development.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.